Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate Cancer
Experts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Revolutionizing Prostate Cancer Imaging with PSMA PET-CT
In the first article of this series, Naveen Kella, MD, discusses the transformative impact of PSMA PET-CT imaging on prostate cancer diagnosis, highlighting its advantages and addressing clinical challenges and guidelines in this evolving field.
Choosing the Right PSMA PET Tracer: Considerations and Insights
Factors impacting the choice between gallium 68 and fluorine 18 PSMA PET tracers, including half-lives, institutional capabilities, access to resources, detection rates, reimbursement constraints, and potential differences in interpretation.
Prostate Cancer: PSMA PET CT Guidelines and Collaboration
Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, discuss the consensus between clinical guidelines for PSMA PET CT usage in prostate cancer, emphasizing multidisciplinary collaboration and the importance of urologists' involvement.
Evolution of PSMA PET-CT Imaging in Patients With Prostate Cancer
Expert urologist Naveen Kella, MD, shares his perspective on the advent of PSMA PET-CT imaging in patients with prostate cancer, addressing both benefits and limitations to this approach.
Transformative Impact of PSMA PET Imaging on Patient Management
Key opinion leaders discuss how PSMA PET CT tracers, including gallium 68 and fluorine 18, are revolutionizing prostate cancer patient management and with accurate and early detection of disease spread.
PSMA PET Tracer Comparison: Accuracy and Access in Prostate Cancer
A review of available PSMA PET tracers for prostate cancer detection, covering sensitivity, specificity, access to therapy, and reimbursement impacting patient care.
PSMA PET Imaging Tracers: Gallium 68 vs. Fluorine 18 in Prostate Cancer
Shared insight into FDA-approved PSMA PET imaging tracers, highlighting similarities and differences between gallium 68 and fluorine 18 compounds.
Optimizing PSMA PET CT: Targeted Imaging Guidelines
Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, delve into patient selection for PSMA PET CT scans, discussing indications spanning initial diagnosis and recurrence, as well as institution guidelines.
Urologists' Insight Into the Evolution of PSMA-PET in Prostate Cancer
Experts explore PSMA's significance in prostate cancer imaging, covering its expression, limitations, and transformative role in detecting even low PSA recurrences with PSMA-PET technology.
Revolutionizing Prostate Cancer Imaging: Traditional Techniques vs. PSMA-PET
In this introductory dialogue, Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, discuss PSMA-PET's transformative role alongside conventional techniques in prostate cancer imaging.
2 Clarke Drive Cranbury, NJ 08512